Compare HBCP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBCP | VALN |
|---|---|---|
| Founded | 1908 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 536.9M |
| IPO Year | 2008 | 2021 |
| Metric | HBCP | VALN |
|---|---|---|
| Price | $64.68 | $6.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $63.50 | $16.00 |
| AVG Volume (30 Days) | ★ 142.5K | 137.7K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ 29.01 | N/A |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | $93.87 |
| P/E Ratio | $11.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.75 | $5.43 |
| 52 Week High | $65.95 | $12.25 |
| Indicator | HBCP | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 29.06 |
| Support Level | $56.72 | $5.95 |
| Resistance Level | N/A | $6.73 |
| Average True Range (ATR) | 2.00 | 0.28 |
| MACD | 0.52 | 0.01 |
| Stochastic Oscillator | 84.18 | 32.49 |
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.